NovoCure Limited
NVCR
$15.23
$0.030.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.95% | 8.48% | 8.28% | 11.17% | 14.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.95% | 8.48% | 8.28% | 11.17% | 14.58% |
| Cost of Revenue | 11.76% | 17.42% | 21.29% | 15.98% | 11.78% |
| Gross Profit | 10.71% | 5.85% | 4.51% | 9.70% | 15.47% |
| SG&A Expenses | 5.26% | 6.77% | -3.11% | 15.18% | 14.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.61% | 9.10% | 4.00% | 11.48% | 9.53% |
| Operating Income | 9.75% | -11.49% | 11.49% | -12.65% | 6.07% |
| Income Before Tax | -7.48% | -34.97% | -3.88% | -31.45% | -0.66% |
| Income Tax Expenses | -114.27% | -106.30% | -100.06% | -23.08% | 4.76% |
| Earnings from Continuing Operations | 13.09% | -5.40% | 19.21% | -18.60% | -1.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.09% | -5.40% | 19.21% | -18.60% | -1.33% |
| EBIT | 9.75% | -11.49% | 11.49% | -12.65% | 6.07% |
| EBITDA | 12.88% | -9.92% | 14.28% | -11.69% | 7.04% |
| EPS Basic | 16.12% | -1.53% | 21.71% | -15.64% | 0.87% |
| Normalized Basic EPS | -3.27% | -24.50% | 3.20% | -25.22% | 0.23% |
| EPS Diluted | 16.13% | -1.54% | 21.70% | -15.66% | 0.86% |
| Normalized Diluted EPS | -3.27% | -24.50% | 3.20% | -25.22% | 0.23% |
| Average Basic Shares Outstanding | 3.59% | 3.49% | 3.32% | 2.80% | 2.30% |
| Average Diluted Shares Outstanding | 3.59% | 3.49% | 3.32% | 2.80% | 2.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |